Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action

Stephen E. Braun, Keyue Chen, Bruce R. Blazar, Paul J. Orchard, George Sledge, Michael J. Robertson, Hal E. Broxmeyer, Kenneth Cornetta

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We have shown that Flk2/Flt3 ligand (Flt3L)-transduced tumor vaccine induces transferable T cell protection against a murine breast cancer cell line, but a direct comparison with the potent effector GM-CSF, the activity against preestablished tumors, and the mechanism of antitumor response in this breast cancer model are not known. We compared vaccination with C3L5 cells expressing FIt3L (C3Lt-Flt3L) and GM-CSF (C3L5GMCSF) by injecting 1 x 104 cells subcutaneously into the chest wall and then, after 4 weeks, challenging the contralateral chest of tumor-free mice with parental C3L5 cells. C3L5-Flt3L and C3L5-GMCSF had reduced in vivo growth rates (25% tumor formation each) compared with 100% tumor formation of C3L5 cells expressing only neomycin phosphotransferase (C3L5-G1N). However, when tumor-free animals were challenged with parental C3L5 cells, C3L5-Flt3L vaccination was significantly better at preventing tumor growth (p < 0.05) than C3L5-GMCSF vaccination (33% of C3L5-Flt3L-vaccinated animals developed tumor compared with 77% of C3L5-GMCSF-vaccinated animals). Adoptive transfer of immunity for both vaccines was demonstrated; splenic T cells from tumor-free mice protected naive mice from parental tumor challenge. To simulate minimal disease, parental C3L5 cells at two concentrations (high, 5 x 103 cells; or low, 1 x 103 cells) were injected into the contralateral chest wall 4 days prior to treatment with C3L5-G1N or C3L5-Flt3L. C3L5Flt3L treatment decreased contralateral parental tumor formation (high, 67% tumor free; low, 90% tumor free) compared with C3L5-G1N treatment (high and low, 0% tumor free). Immunodepletion of activated natural killer cells with anti-asialo-GM1 blocked C3L5-Flt3L- and C3L5 plus soluble Flt3L-mediated antitumor activity. Thus, Flt3L-transduced tumor cells manifest potent antitumor activity, apparently mediated, at least partially, by natural killer cells.

Original languageEnglish (US)
Pages (from-to)2141-2151
Number of pages11
JournalHuman Gene Therapy
Volume10
Issue number13
DOIs
StatePublished - Sep 1 1999

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Action Potentials
Breast Neoplasms
Neoplasms
Vaccination
Thoracic Wall
flt3 ligand protein
Natural Killer Cells
Kanamycin Kinase
T-Lymphocytes
Cancer Vaccines
Cytoprotection
Adoptive Transfer
Adaptive Immunity
Growth
Thorax
Therapeutics
Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Flt3 ligand antitumor activity in a murine breast cancer model : A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. / Braun, Stephen E.; Chen, Keyue; Blazar, Bruce R.; Orchard, Paul J.; Sledge, George; Robertson, Michael J.; Broxmeyer, Hal E.; Cornetta, Kenneth.

In: Human Gene Therapy, Vol. 10, No. 13, 01.09.1999, p. 2141-2151.

Research output: Contribution to journalArticle

@article{c0fa2e73200e4b4f95fb493dc50a848f,
title = "Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action",
abstract = "We have shown that Flk2/Flt3 ligand (Flt3L)-transduced tumor vaccine induces transferable T cell protection against a murine breast cancer cell line, but a direct comparison with the potent effector GM-CSF, the activity against preestablished tumors, and the mechanism of antitumor response in this breast cancer model are not known. We compared vaccination with C3L5 cells expressing FIt3L (C3Lt-Flt3L) and GM-CSF (C3L5GMCSF) by injecting 1 x 104 cells subcutaneously into the chest wall and then, after 4 weeks, challenging the contralateral chest of tumor-free mice with parental C3L5 cells. C3L5-Flt3L and C3L5-GMCSF had reduced in vivo growth rates (25{\%} tumor formation each) compared with 100{\%} tumor formation of C3L5 cells expressing only neomycin phosphotransferase (C3L5-G1N). However, when tumor-free animals were challenged with parental C3L5 cells, C3L5-Flt3L vaccination was significantly better at preventing tumor growth (p < 0.05) than C3L5-GMCSF vaccination (33{\%} of C3L5-Flt3L-vaccinated animals developed tumor compared with 77{\%} of C3L5-GMCSF-vaccinated animals). Adoptive transfer of immunity for both vaccines was demonstrated; splenic T cells from tumor-free mice protected naive mice from parental tumor challenge. To simulate minimal disease, parental C3L5 cells at two concentrations (high, 5 x 103 cells; or low, 1 x 103 cells) were injected into the contralateral chest wall 4 days prior to treatment with C3L5-G1N or C3L5-Flt3L. C3L5Flt3L treatment decreased contralateral parental tumor formation (high, 67{\%} tumor free; low, 90{\%} tumor free) compared with C3L5-G1N treatment (high and low, 0{\%} tumor free). Immunodepletion of activated natural killer cells with anti-asialo-GM1 blocked C3L5-Flt3L- and C3L5 plus soluble Flt3L-mediated antitumor activity. Thus, Flt3L-transduced tumor cells manifest potent antitumor activity, apparently mediated, at least partially, by natural killer cells.",
author = "Braun, {Stephen E.} and Keyue Chen and Blazar, {Bruce R.} and Orchard, {Paul J.} and George Sledge and Robertson, {Michael J.} and Broxmeyer, {Hal E.} and Kenneth Cornetta",
year = "1999",
month = "9",
day = "1",
doi = "10.1089/10430349950017130",
language = "English (US)",
volume = "10",
pages = "2141--2151",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "13",

}

TY - JOUR

T1 - Flt3 ligand antitumor activity in a murine breast cancer model

T2 - A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action

AU - Braun, Stephen E.

AU - Chen, Keyue

AU - Blazar, Bruce R.

AU - Orchard, Paul J.

AU - Sledge, George

AU - Robertson, Michael J.

AU - Broxmeyer, Hal E.

AU - Cornetta, Kenneth

PY - 1999/9/1

Y1 - 1999/9/1

N2 - We have shown that Flk2/Flt3 ligand (Flt3L)-transduced tumor vaccine induces transferable T cell protection against a murine breast cancer cell line, but a direct comparison with the potent effector GM-CSF, the activity against preestablished tumors, and the mechanism of antitumor response in this breast cancer model are not known. We compared vaccination with C3L5 cells expressing FIt3L (C3Lt-Flt3L) and GM-CSF (C3L5GMCSF) by injecting 1 x 104 cells subcutaneously into the chest wall and then, after 4 weeks, challenging the contralateral chest of tumor-free mice with parental C3L5 cells. C3L5-Flt3L and C3L5-GMCSF had reduced in vivo growth rates (25% tumor formation each) compared with 100% tumor formation of C3L5 cells expressing only neomycin phosphotransferase (C3L5-G1N). However, when tumor-free animals were challenged with parental C3L5 cells, C3L5-Flt3L vaccination was significantly better at preventing tumor growth (p < 0.05) than C3L5-GMCSF vaccination (33% of C3L5-Flt3L-vaccinated animals developed tumor compared with 77% of C3L5-GMCSF-vaccinated animals). Adoptive transfer of immunity for both vaccines was demonstrated; splenic T cells from tumor-free mice protected naive mice from parental tumor challenge. To simulate minimal disease, parental C3L5 cells at two concentrations (high, 5 x 103 cells; or low, 1 x 103 cells) were injected into the contralateral chest wall 4 days prior to treatment with C3L5-G1N or C3L5-Flt3L. C3L5Flt3L treatment decreased contralateral parental tumor formation (high, 67% tumor free; low, 90% tumor free) compared with C3L5-G1N treatment (high and low, 0% tumor free). Immunodepletion of activated natural killer cells with anti-asialo-GM1 blocked C3L5-Flt3L- and C3L5 plus soluble Flt3L-mediated antitumor activity. Thus, Flt3L-transduced tumor cells manifest potent antitumor activity, apparently mediated, at least partially, by natural killer cells.

AB - We have shown that Flk2/Flt3 ligand (Flt3L)-transduced tumor vaccine induces transferable T cell protection against a murine breast cancer cell line, but a direct comparison with the potent effector GM-CSF, the activity against preestablished tumors, and the mechanism of antitumor response in this breast cancer model are not known. We compared vaccination with C3L5 cells expressing FIt3L (C3Lt-Flt3L) and GM-CSF (C3L5GMCSF) by injecting 1 x 104 cells subcutaneously into the chest wall and then, after 4 weeks, challenging the contralateral chest of tumor-free mice with parental C3L5 cells. C3L5-Flt3L and C3L5-GMCSF had reduced in vivo growth rates (25% tumor formation each) compared with 100% tumor formation of C3L5 cells expressing only neomycin phosphotransferase (C3L5-G1N). However, when tumor-free animals were challenged with parental C3L5 cells, C3L5-Flt3L vaccination was significantly better at preventing tumor growth (p < 0.05) than C3L5-GMCSF vaccination (33% of C3L5-Flt3L-vaccinated animals developed tumor compared with 77% of C3L5-GMCSF-vaccinated animals). Adoptive transfer of immunity for both vaccines was demonstrated; splenic T cells from tumor-free mice protected naive mice from parental tumor challenge. To simulate minimal disease, parental C3L5 cells at two concentrations (high, 5 x 103 cells; or low, 1 x 103 cells) were injected into the contralateral chest wall 4 days prior to treatment with C3L5-G1N or C3L5-Flt3L. C3L5Flt3L treatment decreased contralateral parental tumor formation (high, 67% tumor free; low, 90% tumor free) compared with C3L5-G1N treatment (high and low, 0% tumor free). Immunodepletion of activated natural killer cells with anti-asialo-GM1 blocked C3L5-Flt3L- and C3L5 plus soluble Flt3L-mediated antitumor activity. Thus, Flt3L-transduced tumor cells manifest potent antitumor activity, apparently mediated, at least partially, by natural killer cells.

UR - http://www.scopus.com/inward/record.url?scp=0033199589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033199589&partnerID=8YFLogxK

U2 - 10.1089/10430349950017130

DO - 10.1089/10430349950017130

M3 - Article

C2 - 10498246

AN - SCOPUS:0033199589

VL - 10

SP - 2141

EP - 2151

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 13

ER -